Image source: Shutterstock

Highlights

  • Hoth Therapeutics files amended patent claims for HT-KIT targeting inflammatory diseases.
  • The company initiates a preclinical toxicity study for HT-KIT to evaluate safety.
  • HT-KIT’s development aims for clinical readiness and potential partnerships.

Hoth Therapeutics, Inc. (NASDAQ: HOTH) has announced significant progress in the development of its proprietary antisense oligonucleotide (ASO) drug candidate, HT-KIT. The biopharmaceutical company is focused on creating therapies for allergic and inflammatory diseases, and HT-KIT represents an innovative approach to treating conditions such as anaphylaxis, mastocytosis, and allergic asthma.

The company has filed amended claims with the U.S. Patent and Trademark Office for its lead ASO technology. This technology targets two key genes—MS4A6A and FceRIß—that are involved in allergic inflammation and mast cell-related diseases. These enhanced claims are designed to strengthen the intellectual property protection for HT-KIT, positioning the drug as a novel therapeutic platform with wide clinical potential.

Alongside the patent advancements, Hoth has initiated a four-week intravenous toxicity study in C57BL/6 mice to assess the safety profile of HT-KIT. This study, conducted with the support of OnTargetx R&D Inc. and ITR Laboratories, aims to evaluate multiple dose groups and includes detailed pathology assessments and pharmacokinetic profiling. The results from this preclinical study will help inform future regulatory filings as Hoth moves toward clinical trials.

Hoth's CEO, Robb Knie, commented on the progress, stating that these milestones demonstrate the growing momentum behind HT-KIT as the company works towards clinical readiness. The strengthened patent position, combined with a comprehensive preclinical package, is expected to play a key role in advancing the drug candidate to the next stages of development and securing potential partnerships.